Up-and-coming Henlius Biotech consolidates its footing in the biosimilar world with another regulatory approval.
Shanghai Henlius Biotech reached another regulatory milestone as China’s National Medical Products Administration (NMPA) approved its trastuzumab biosimilar (HLX02; Zercepac [European name]) for marketing.
The product in late July also was approved by the European Commission. These regulatory nods make HLX02 the first monoclonal antibody developed in China to be approved in both China and the European Union.
The biosimilar is indicated for the treatment of HER2-positive early stage breast cancer, HER2-positive metastatic breast cancer, and HER2-postive metastatic gastric cancer. These indications correspond to the approved indications in China for the trastuzumab originator product, which has been included on China’s National Reimbursement Drug List since 2017.
Henlius said that results from analytical studies, preclinical studies, a phase 1 clinical study, and a global multicenter phase 3 clinical study demonstrated that HLX02 “is highly similar to the reference trastuzumab in terms of quality, safety and efficacy.”
“The approval of HLX02 will improve the accessibility of trastuzumab in China and further strengthen the standardized treatment of patients with HER2-positive breast and gastric cancer," said Binghe Xu, principal investigator of the phase 3 study.
Wenjie Zhang, president of Henlius, said HLX02 marks the second of the company’s products approved for launch. The first was a rituximab biosimilar (HLX01), launched in China and marking that country’s first approved biosimilar. The approval for this drug, used in oncology and for autoimmune diseases, came in February 2019.
In April, the company announced that its new drug application for a denosumab biosimilar was accepted for review by the NMPA. The drug is intended for the osteoporosis market.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.